{"id":"W4415013760","doi":"10.1016/j.ccell.2025.09.009","title":"Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial","year":2025,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"Key Research and Development Program of Zhejiang Province; National Key Research and Development Program of China; Science and Technology Department of Zhejiang Province; Natural Science Foundation of Jiangxi Province; National Natural Science Foundation of China","keywords":"FOLFIRINOX; Gemcitabine; Hazard ratio; Regimen; Clinical endpoint; Neoadjuvant therapy; Confidence interval; Adverse effect; Adjuvant","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001804587,0.002507618,0.003745952,0.0005017378,0.0006098249,0.00176419,0.001119597,0.001583942,0.006697773],"category_scores_gemma":[0.001142679,0.0009655825,0.002708784,0.0006415497,0.002184686,0.00187952,0.000655753,0.004659263,0.001497616],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001625188,"about_ca_system_score_gemma":0.002122925,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001461505,"about_ca_topic_score_gemma":0.004424714,"domain_scores_codex":[0.9993518,0.0003153213,0.00003311245,0.000133517,0.00003599653,0.0001303169],"domain_scores_gemma":[0.9991708,0.000166287,0.0001609859,0.00009810641,0.00003185359,0.0003720184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9766962,0.006823733,0.0005398717,0.000308073,0.0008183474,0.0000294632,0.00005756722,0.0007814749,0.002001,0.00009640273,0.0007582871,0.01108961],"study_design_scores_gemma":[0.8983412,0.09763503,0.001535894,0.00003525901,0.0006004524,0.0000418077,0.00003477917,0.0004854376,0.0003965003,0.0002159293,0.0006547199,0.00002311375],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892282,0.003378936,0.0006758909,0.000856426,0.0006416555,0.002195772,0.0009393799,0.0001425475,0.001941159],"genre_scores_gemma":[0.9836728,0.003152634,0.002098745,0.001475157,0.0004304022,0.003465377,0.001896094,0.00006640708,0.00374248],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006697773,"threshold_uncertainty_score":0.02240628,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03838965553033384,"score_gpt":0.4005066183083725,"score_spread":0.3621169627780386,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}